Gilead Sciences, Inc. $GILD Shares Sold by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,590 shares of the biopharmaceutical company’s stock after selling 1,070 shares during the period. EagleClaw Capital Managment LLC’s holdings in Gilead Sciences were worth $952,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of GILD. Vanguard Group Inc. raised its stake in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the period. Geode Capital Management LLC increased its holdings in shares of Gilead Sciences by 2.6% during the 2nd quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Gilead Sciences by 314.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after acquiring an additional 11,156,382 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Gilead Sciences by 12.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after acquiring an additional 1,520,809 shares during the period. Finally, Nuveen LLC acquired a new stake in Gilead Sciences during the first quarter worth about $620,415,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Up 0.7%

Shares of NASDAQ:GILD opened at $123.40 on Thursday. The company has a market capitalization of $153.10 billion, a price-to-earnings ratio of 24.58, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The company has a 50 day moving average of $116.99 and a two-hundred day moving average of $112.55. Gilead Sciences, Inc. has a 52-week low of $86.08 and a 52-week high of $124.87. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on GILD shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $133.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. Royal Bank Of Canada increased their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research report on Friday, October 31st. Wolfe Research lifted their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research note on Friday, October 31st. Finally, Truist Financial reissued a “buy” rating and issued a $145.00 target price (up previously from $127.00) on shares of Gilead Sciences in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $128.27.

Insider Activity

In other news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $354,240.00. Following the sale, the insider directly owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. The trade was a 2.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $295,200.00. Following the completion of the transaction, the chief financial officer directly owned 157,055 shares of the company’s stock, valued at $18,545,054.40. This represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 71,500 shares of company stock worth $8,336,040 over the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.